BMRN FY2025 EPS Forecast Boosted by Cantor Fitzgerald

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) – Cantor Fitzgerald raised their FY2025 earnings per share (EPS) estimates for shares of BioMarin Pharmaceutical in a research report issued to clients and investors on Friday, May 2nd. Cantor Fitzgerald analyst O. Brayer now anticipates that the biotechnology company will earn $3.61 per share for the year, up from their prior forecast of $3.53. Cantor Fitzgerald has a “Overweight” rating and a $90.00 price objective on the stock. The consensus estimate for BioMarin Pharmaceutical’s current full-year earnings is $3.15 per share.

BioMarin Pharmaceutical (NASDAQ:BMRN) last posted its quarterly earnings data on Wednesday, February 19th. The biotechnology company reported $0.72 EPS for the quarter, topping analysts’ consensus estimates of $0.54 by $0.18. The company had revenue of $747.31 million during the quarter, compared to the consensus estimate of $711.05 million. BioMarin Pharmaceutical had a net margin of 14.96% and a return on equity of 9.91%.

Several other research firms have also issued reports on BMRN. Citigroup dropped their price target on shares of BioMarin Pharmaceutical from $82.00 to $78.00 and set a “neutral” rating on the stock in a research report on Friday, May 2nd. Oppenheimer upgraded BioMarin Pharmaceutical from a “market perform” rating to an “outperform” rating and set a $98.00 price objective on the stock in a research note on Monday, February 24th. Bank of America increased their price target on BioMarin Pharmaceutical from $99.00 to $103.00 and gave the company a “buy” rating in a research note on Thursday, February 20th. Scotiabank raised their target price on shares of BioMarin Pharmaceutical from $78.00 to $80.00 and gave the stock a “sector perform” rating in a research note on Thursday, February 20th. Finally, Wedbush reissued an “outperform” rating and issued a $94.00 price target on shares of BioMarin Pharmaceutical in a report on Thursday, February 20th. Seven research analysts have rated the stock with a hold rating, seventeen have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $93.45.

BioMarin Pharmaceutical Stock Down 3.8 %

BMRN stock opened at $59.67 on Monday. BioMarin Pharmaceutical has a twelve month low of $52.93 and a twelve month high of $94.85. The company has a market cap of $11.39 billion, a price-to-earnings ratio of 27.12, a P/E/G ratio of 0.61 and a beta of 0.27. The company has a quick ratio of 2.62, a current ratio of 5.33 and a debt-to-equity ratio of 0.11. The business has a 50 day moving average price of $65.52 and a two-hundred day moving average price of $65.62.

Institutional Investors Weigh In On BioMarin Pharmaceutical

Institutional investors have recently modified their holdings of the company. Farther Finance Advisors LLC grew its holdings in BioMarin Pharmaceutical by 95.9% during the 1st quarter. Farther Finance Advisors LLC now owns 431 shares of the biotechnology company’s stock worth $29,000 after acquiring an additional 211 shares during the period. LRI Investments LLC increased its holdings in BioMarin Pharmaceutical by 856.9% in the fourth quarter. LRI Investments LLC now owns 488 shares of the biotechnology company’s stock worth $32,000 after purchasing an additional 437 shares in the last quarter. MassMutual Private Wealth & Trust FSB lifted its stake in BioMarin Pharmaceutical by 71.2% in the first quarter. MassMutual Private Wealth & Trust FSB now owns 524 shares of the biotechnology company’s stock valued at $37,000 after buying an additional 218 shares during the period. SBI Securities Co. Ltd. acquired a new stake in shares of BioMarin Pharmaceutical during the 4th quarter worth approximately $36,000. Finally, CIBC Private Wealth Group LLC increased its stake in shares of BioMarin Pharmaceutical by 64.2% in the 4th quarter. CIBC Private Wealth Group LLC now owns 596 shares of the biotechnology company’s stock valued at $41,000 after acquiring an additional 233 shares in the last quarter. 98.71% of the stock is owned by institutional investors.

Insider Activity

In other BioMarin Pharmaceutical news, CAO Erin Burkhart sold 1,295 shares of the company’s stock in a transaction dated Wednesday, March 19th. The stock was sold at an average price of $71.52, for a total value of $92,618.40. Following the sale, the chief accounting officer now owns 16,955 shares in the company, valued at approximately $1,212,621.60. The trade was a 7.10 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Over the last three months, insiders have sold 2,912 shares of company stock valued at $202,244. 0.85% of the stock is currently owned by corporate insiders.

About BioMarin Pharmaceutical

BioMarin Pharmaceutical Inc develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease.